MVision AI Segmentation

by MVision AI  · Based in Finland → — Automate Smarter, Treat Faster.
Nuclear Medicine Oncology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

MVision AI provides advanced AI-powered solutions for radiotherapy treatment planning, primarily focusing on automatic segmentation and dose prediction. Its flagship products, such as Contour+ and Dose+, are part of the comprehensive Guideline-Based Segmentation (GBS™) suite and the Workspace+ platform. These tools are designed to automate repetitive tasks, standardize contouring, and streamline the radiotherapy workflow, ultimately aiming to reduce treatment planning time and enhance the quality and consistency of cancer care.

The technology leverages deep learning models to generate precise 3D delineations of organs-at-risk (OARs) and lymph node areas, adhering to international consensus guidelines like ESTRO and RTOG. This automation can significantly reduce manual work for radiation oncology professionals, allowing them to focus on more complex tasks and patient-facing care. MVision AI’s solutions are clinically evaluated and designed for seamless integration with existing DICOM-compliant treatment planning systems.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered auto-segmentation (Contour+)
  • AI-powered dose prediction (Dose+)
  • Guideline-Based Segmentation (GBSu2122) suite
  • Synthetic imaging (Image+)
  • Contour assessment (Verify)
  • Guideline training environment (Guide)
  • Reduces manual contouring work by up to 95%
  • Enhances planning consistency and reduces inter-planner variability
  • Seamless integration with DICOM-compliant Treatment Planning Systems (TPS)
  • Cloud-based and on-premises deployment options

Use Cases

  • Radiotherapy treatment planning for various cancer types
  • Automated delineation of organs-at-risk (OARs)
  • Automated delineation of lymph node areas
  • Personalized dose planning and optimization for radiation therapy
  • Reducing treatment planning time and improving workflow efficiency
  • Standardizing contouring and reducing inter-observer variability in clinics

What Physicians Need to Know

Key Capabilities
AI-powered auto-segmentation for over 300 organs-at-risk (OARs) and lymph node areas across major anatomical sites (e.g., head and neck, breast, thorax, abdomen, pelvis, brain CT/MR). It generates precise 3D models in minutes, reducing manual contouring work by up to 95% and boosting consistency by 20%. The solution is part of the Guideline-Based Segmentation (GBSu2122) suite, which includes tools for training and contour assessment.
Clinical Utility
Significantly reduces contouring time (median 29-79% time savings), improves contour consistency and accuracy, and decreases inter-observer variability. It boasts high clinical acceptability, with 87% of radiation oncologists reporting contours required minor or no editing. The tool adheres to international guidelines (ESTRO, RTOG), enabling standardized contours and allowing clinicians to focus on patient care. It also has minimal impact on radiation dose distribution and facilitates advanced techniques like VMAT.
Integration Options
Available in both cloud-based and local deployment modes, ensuring compatibility with all radiotherapy treatment planning systems (TPS). It integrates into existing DICOM networks, often via a daemon server, and supports web browser-based interfaces or direct API calls. Advanced operations allow for customization of AI-generated structures.
Compliance Status
CE marked and FDA 510(k) cleared. It is GDPR and HIPAA compliant, with encrypted and pseudonymized data handling. The system adheres to ISO 13485:2016 quality standards and FDA 21 CFR 820 Quality System regulations. MVision AI Segmentation has received market clearances in various regions, including the UAE, Australia (TGA for MR models), Singapore, and South Korea.
Pricing Model
Typically offered either as a fixed annual fee or on a per-patient basis. Potential additional costs may include cloud hosting, proprietary hardware, local server maintenance, local training, updates, and support.
User Experience
Users report high satisfaction, with senior radiation oncologists rating it significantly higher. The tool's effectiveness in reducing manual adjustment time is consistent across all experience levels. It aims to reduce workload and build trust in AI by providing insights into its predictions.
Support Quality
Offers vendor support tools and supplementary functionalities to enhance user experience. MVision AI provides assistance with advanced structure operations and offers support via email for compatibility issues or compromised results. The AI team continuously upgrades the product in collaboration with research partners.
Implementation Complexity
Integration into the DICOM network is guided by MVision AI. Cloud deployment simplifies updates and hardware management, while a local solution is available for stricter data protection. It requires additional software (e.g., MVision Daemon) for DICOM file handling and mandates maintained antivirus/malware protection. There is a learning curve, but it leads to significant efficiency gains.
Evidence Base
Supported by numerous peer-reviewed studies across 17 clinics in 12 countries, involving 64 evaluators and over 16,000 volumes of interest on 1,242 scans. These studies confirm high accuracy (median Dice Similarity Coefficient around 0.87-0.88), clinical acceptability, and substantial time savings, along with reduced inter-observer variability and minimal impact on dose distribution.
Physician Tip

MVision AI Segmentation can dramatically reduce contouring time and improve consistency in radiotherapy planning. Leverage the Guideline-Based Segmentation (GBSu2122) suite, including 'Guide' for training and 'Verify' for contour assessment, to enhance your team's expertise and build confidence in AI-generated contours. While the tool offers high accuracy, always perform a critical review of AI-generated contours before clinical use, especially for complex cases. Utilize the customization options to fine-tune structures according to local clinical preferences and protocols.

MVision AI Segmentation offers flexible integration via cloud or local deployment and is compatible with all major radiotherapy treatment planning systems. Ensure your IT infrastructure is prepared for DICOM network integration, potentially requiring the MVision Daemon for data routing and de-identification. For cloud deployments, easy updates are a benefit, while local solutions address stringent data protection needs. Direct API access allows for advanced scripting and workflow automation within your existing TPS.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Contact for pricing
DeploymentCloud-based and On-premises (local daemon server)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

MVision AI received 510(k) clearance (K212915) from the U.S. Food and Drug Administration (FDA) on May 31, 2022, for its guideline-based, AI-powered software for automatic segmentation for radiotherapy, specifically for its Contour+ (MVision AI Segmentation) software system.
Integrations
EHR Not specified
Specialties Nuclear Medicine, Oncology, Radiology

What the Web Says

MVision AI Segmentation is a cloud-based, AI-powered auto-contouring software designed to streamline radiotherapy treatment planning by automating the segmentation of organs-at-risk and lymph node areas. It aims to reduce contouring time, improve consistency, and enhance the overall quality of cancer care. The platform includes Contour+ for segmentation, Guide for training, and Verify for contour assessment.

Overall: Positive

Strengths

  • Significantly reduces contouring time, with reported reductions of up to 95% and median time for AI contour generation being 2.3 minutes compared to 25 minutes for manual contouring.
  • Improves consistency and standardization of contours, aligning with official guidelines like ESTRO and RTOG.
  • High quality and accurate contours, with 87% of radiation oncologists in one study scoring the solution as requiring minor or no editing.
  • Enhances clinical workflow efficiency, allowing for shorter waiting times and potentially same-day treatment for some patients.
  • Helpful for both junior and senior radiation oncologists, with manual adjustment time not differing based on experience.
  • Decreases interobserver variability compared to manual contouring.

Limitations

  • Some users on Reddit have expressed preferences for other AI contouring solutions like Limbus or Radformation due to perceived better accuracy or workflow.
  • The system is not intended for use with real-time adaptive planning workflows.
  • Automated stomach segmentation can be challenging due to variations in size, shape, and position, requiring subsequent supervision by medical physicists and radiation oncologists.
  • While generally positive, some studies indicate that contours still require review, modification, and approval by a medical professional.
  • MRI models may not be available in all regions (e.g., Australia, subject to TGA approval).

Based on reviews from: MVision AI, alphaXRT, XRT Medical, PubMed Central (PMC), Medical Product Outsourcing (MPO), Voima Ventures, Reddit, accessdata.fda.gov, MDPI

Last updated: 2026-07-18

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate MVision AI Segmentation

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

MVision AI
MVision AI Receives MFDS Approval and Market Authorization for South Korea
MVision AI has received approval from the Ministry of Food and Drug Safety (MFDS) in South Korea for its MVision AI Segmentation (Contour+) software, enabling its use in radiation therapy treatment planning workflows. This approval is a significant milestone for MVision AI's expansion beyond Europe and the US.
2024-06
MVision AI
MVision AI's Workspace+ Receives TGA Approval in Australia
MVision AI announced that its Workspace+ platform has received market approval from the Therapeutic Goods Administration (TGA) in Australia. This allows for the use of Workspace+ in Australian healthcare settings.
2026-02
MVision AI
MVision AI Secures FDA 510(k) Clearance for Contour+ Advanced CT and MR Models
MVision AI has received FDA 510(k) clearance for its Contour+ software, specifically for its advanced CT and MR models. This clearance allows the software to be used in radiation therapy treatment planning workflows in the United States.
2024-10
PMC (Peer-Reviewed Journal)
From research to reality: The role of artificial intelligence applications in HCC care
This article discusses the role of AI applications in hepatocellular carcinoma (HCC) care, listing MVision AI's Segmentation among other applications predominantly designed for radiation therapy planning. It highlights the increasing utilization of selective internal radiation therapy in HCC care.
2024-04
MVision AI
MVision AI announces first Health Canada Medical Device License for MVision AI Segmentation (Contour+)
MVision AI has received its first Health Canada Medical Device License for MVision AI Segmentation (Contour+). This allows the use of their AI-powered segmentation software in Canada for radiation therapy planning.
2024-01
MVision AI
MVision AI launches Contour+ auto-contouring to facilitate standardization and shorten time to treatment for cancer radiotherapy
MVision AI announced the launch of its Contour+ auto-contouring software, version 1.2.4, designed to standardize and accelerate the radiotherapy treatment planning process for cancer patients. This solution aims to reduce contouring time in oncology departments.
2023-08
MVision AI (Tech Magazine/Article)
Man vs. Machine (Learning): Comparing Speed and Cost-Effectiveness of Manual vs. Deep Learning Segmentation-Aided Volume Delineation for Head and Neck Lymph Node Targets
This preliminary study, featured in a tech magazine, compares manual and AI-based segmentation for head and neck lymph node delineation, suggesting that an AI-aided approach can be feasible and efficient. The article highlights the potential for AI to save time and improve cost-effectiveness in radiotherapy planning.
2023-10
ESTRO 2023 (Industry Symposium)
MVision AI segmentation for brain MRI
MVision AI presented on its segmentation capabilities for brain MRI at the ESTRO 2023 conference in Vienna, Austria. This oral presentation was part of an industry symposium.
2023-05

Videos

Product demos, reviews, and walkthroughs for MVision AI Segmentation.

View all on YouTube

Frequently Asked Questions

MVision AI Segmentation, specifically Contour+, seamlessly integrates with existing radiotherapy treatment planning systems, operating either as a cloud-based or local solution. It automates the delineation of organs-at-risk (OARs) and lymph node areas, significantly reducing manual contouring time by up to 95% and enhancing consistency across different users and clinics.
MVision AI Segmentation is compliant with GDPR and HIPAA regulations, ensuring robust data protection and patient privacy. Patient scans are encrypted and pseudonymized before being processed in the cloud, and the data is deleted from cloud servers within 24 hours, with the clinic retaining full control as the data controller. The product also holds CE Mark certification (including MDR for Contour+ and Class IIa for Workspace+) and 510(k) clearance, affirming its safety and performance as a medical device.
While highly accurate, MVision AI Segmentation is not intended for detecting lesions or tumors, nor for use in real-time adaptive planning workflows. Physicians must critically review and potentially modify the AI-generated contours, especially for Gross Target Volumes (GTVs), Clinical Target Volumes (CTVs), and organs-at-risk located close to target volumes, to ensure personalized and safe treatment.
Several other AI auto-segmentation solutions are available, including those from Mirada, Radformation, RayStation, and TheraPanacea, as well as broader AI platforms like Roboflow and Google Cloud Vision API. MVision AI's Contour+ is distinguished by its training on international guidelines (e.g., RTOG, ESTRO) and comprehensive coverage of over 300 structures, aiming for standardized and consistent contours.
While specific pricing details for MVision AI are not publicly disclosed, similar cloud-based healthcare AI solutions typically operate on a predictable, transparent subscription pricing model. This approach generally includes setup, training, and ongoing support, rather than a one-time purchase.
MVision AI's Contour+ generates highly accurate and consistent segmentations, trained on extensive datasets aligned with international contouring guidelines. Studies have shown that it significantly reduces inter-observer variability compared to manual contouring, with most AI-generated contours requiring only minor or no edits. However, all AI-generated contours still require critical review and approval by a medical professional to ensure clinical acceptability and patient safety.

Related Tools

FAITH project (Fatigue Therapy – AI-supported Diagnosis and Therapy of Tumour-associated Fatigue Syndrome)
Fimo Health GmbH (Consortium Leader)
Mental & Behavioral Health AI
The FAITH project is developing an AI-based solution for the diagnosis and therapy of tumor-associated fatigue syndrome in cancer patients. It uses wearable sensors, a smartphone app, and artificial intelligence to provide individualized therapy recommendations and monitor mental health.
AI-based support system for skin cancer diagnostics
German Cancer Research Center (DKFZ)
Clinical Decision Support & Reference
Scientists at the German Cancer Research Center have developed an AI-based support system for skin cancer diagnostics that explains its decisions, increasing doctors' confidence in both the AI and their own diagnoses.
eyonis® LCS
Median Technologies
Oncology AI
eyonis® LCS is an FDA 510(k) cleared AI/machine learning-powered software for the detection and diagnosis of lung cancer, helping clinicians detect and characterize suspicious parenchymal pulmonary nodules earlier on low-dose CT scans.
Lumea Digital Pathology
Lumea
Clinical Decision Support & Reference
Lumea is a specialty-specific digital pathology platform that covers the entire diagnostic workflow, from biopsy to final report, and integrates AI tools from partners like Paige and Mindpeak.
Azra AI
Azra AI
Clinical Decision Support & Reference
Azra AI is an AI platform that swiftly analyzes, identifies, and classifies cancer patients, triaging those needing therapy and follow-up to enhance oncology care. It is deployed at more than 1,500 sites and integrated with leading EHRs.
Custom subscription model
Trial Library
Trial Library
Drug Discovery & Research
Trial Library's AI-native platform is embedded in community oncology practices to identify eligible patients for oncology clinical trials. It integrates clinical trials into routine care, activating providers, identifying eligible patients, and navigating them through the trial lifecycle across health systems, biopharma, and payers.

See all Oncology AI tools →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18

Investors who backed MVision AI Segmentation

Funded through the company that built this tool.

Alexia Ventures
VC AI T2
Sao Paulo, Brazil
$1M-$5M
Alexia Ventures is a Sao Paulo-based AI-focused fund backing data-driven software founders aiming at regional enterprise markets, with healthcare software and clinical…
AI/ML in Healthcare Health IT / Healthcare Software
AI Tool Finder
AI-powered search. Results may not be comprehensive.